Re: Rivaroxaban for Thromboprophylaxis in High-risk Ambulatory Patients with Cancer

Affiliations

¹ Department of Urology, University of Zurich, Zurich, Switzerland. Electronic address: christian.fankhauser@usz.ch.
² Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
³ Hematology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Free article

Comment

Christian Daniel Fankhauser et al. Eur Urol. 2020 Mar.

Free article

. 2020 Mar;77(3):388-390.

doi: 10.1016/j.eururo.2019.10.019. Epub 2019 Nov 9.

¹ Department of Urology, University of Zurich, Zurich, Switzerland. Electronic address: christian.fankhauser@usz.ch.
² Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
³ Hematology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

No abstract available

Comment on

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.
Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, Kuruvilla P, Hill D, Spadafora S, Marquis K, Trinkaus M, Tomiak A, Lee AYY, Gross PL, Lazo-Langner A, El-Maraghi R, Goss G, Le Gal G, Stewart D, Ramsay T, Rodger M, Witham D, Wells PS; AVERT Investigators. Carrier M, et al. N Engl J Med. 2019 Feb 21;380(8):711-719. doi: 10.1056/NEJMoa1814468. Epub 2018 Dec 4. N Engl J Med. 2019. PMID: 30511879 Clinical Trial.
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.
Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators. Khorana AA, et al. N Engl J Med. 2019 Feb 21;380(8):720-728. doi: 10.1056/NEJMoa1814630. N Engl J Med. 2019. PMID: 30786186 Clinical Trial.